Aurealis Therapeutics

📍 Kuopio, Finland🗓 Founded 2015👥 17 employees💰 Last funded Sep 2020
Biotechnology Research🌐 aurealistherapeutics.com
Website LinkedIn
Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, we are initiating our Phase 2 study in Italy, Germany and Poland, first for DFU. Venous Ulcers and Pressure Ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
1
Finland
1
Frequently asked questions
Who invested in Aurealis Therapeutics?
Aurealis Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Aurealis Therapeutics last raise funding?
The most recent investment in Aurealis Therapeutics recorded on gritt.io was in September 2020.
When was Aurealis Therapeutics founded?
Aurealis Therapeutics was founded in 2015.
What industry is Aurealis Therapeutics in?
Aurealis Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Aurealis Therapeutics based?
Aurealis Therapeutics is headquartered in Kuopio, Finland.